All In Biotech

Drug Trial Radar · NCT05484206

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Sep 21, 2022

Primary completion

Dec 9, 2025

Study completion Dec 9, 2025

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.

Conditions

  • Hepatic Impairment
  • Cirrhosis

Interventions

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection.

  • VIR-3434Drug

    VIR-3434 given by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218Time frame: 5 days
  2. Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218Time frame: 5 days
  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218Time frame: 5 days
  4. Maximum observed Plasma concentration (Cmax) of VIR-3434Time frame: 18 weeks
  5. Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434Time frame: 18 weeks
  6. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434Time frame: 18 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Inland Empire Clinical Trials

    Rialto, California

  • Orange County Research Center

    Tustin, California

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.